Bayer secures FDA approval for Kovaltry haemophilia A drug
Bayer has secured approval from the US Food and Drug Administration (FDA) for Kovaltry to treat children and adults with haemophilia A. Kovaltry is an unmodified full-length recombinant factor VIII product, which is designed to reduce bleeding in patients with hemophilia A when administered prophylactically two or three times a week.
Click on this link for more information.
